Skip to content

Permanent Cerebral Oxymetry Monitoring for Early Diagnosis and Treatment of Delayed Vasospasm After Subarachnoid Hemorrhage

Permanent Cerebral Oxymetry Monitoring for Early Diagnosis and Treatment of Delayed Vasospasm After Subarachnoid Hemorrhage

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04042571
Acronym
COMOVA
Enrollment
50
Registered
2019-08-02
Start date
2019-10-01
Completion date
2022-12-30
Last updated
2026-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subarachnoid Hemorrhage

Keywords

Intracranial oxymetry, Subarachnoid Hemorrhage, Vasospasm

Brief summary

Transcranial Doppler ultrasound (TCD) monitoring and CT-scanner perfusion are useful but imperfect tools to identify vasospasm and allow intervention to avoid infarction. Permanent monitoring of cerebral tissue oximetry (rSO2) by NIRS, a noninvasive method could allow better vasospasm detection. This study will evaluate diagnostic accuracy of cerebral oxymetry (NIRS) -by rSO2 measurement - in order to detect vasospasm in patient with severe subarachnoid hemorrhage compare to standard monitoring tools.

Detailed description

Delayed vasospasm is a serious complication of aneurismal subarachnoid haemorhage (SAH) significantly influencing morbidity and mortality. Mostly observed between days 4 and 10 after aneurismal rupture, its incidence is higher in cases of severe SAH. Vasospasm strongly affects prognisis generating delayed cerebral ischemia. Clinical deterioration (focal neurological deficit) is the best way to detect severe vasospasm. Unfortunately, most of severe SAH are intubated and sedated prohibiting neurological evaluation. In these frequent situations, Transcranial Doppler (TCD), clinical and biological monitoring, CT-scanner (angio-CT and Perfusion-CT), MRI and cerebral angiography are routinely used to detect vasospasm. Yet, these tools have imperfect sensitivity and specificty delaying diagnosis and treatment. Near-InfraRed Spectroscopy (NIRS) is a non-invasive method measuring tissue oxygenation by regional saturation of capillary-oxygenated hemoglobin (rSO2). This technology demonstrated ability to measure cerebral oxygenation and has previously been reported to monitor carotid and pediatric surgery. To date a few studies also reported NIRS monitoring feasability in post-SAH vasospasm. Our aim is here to evaluate NIRS monitoring for the diagnosis of vasospasm in severe SAH.

Interventions

DEVICECerebral oxymetry monitoring (NIRS)

Near-InfraRed Spectroscopy (NIRS) is a non-invasive method measuring tissue oxygenation by regional saturation of capillary-oxygenated hemoglobin (rSO2). Starting on day 4 after aneurismal rupture NIRS electrods will be placed and maintained until day 12 permanently and blindly recording rSO2. Patients will be monitored following daily practice recommandations inclunding vasospasm detection and treatment.

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men and women * Age ≥ 18 years * HSA of aneurysmal etiology less than 4 days before inclusion diagnosed by clinical presentation and emergency imaging * HSA "severe" defined according to the WFNS ≥ III * Intubated-ventilated patient or any other reason preventing a contributing neurological examination * Affiliate or beneficiary of a social security scheme * Free, informed and written consent signed by the representative

Exclusion criteria

* Age \<18 years * Significant vasospasm as soon as the detection was detected on the initial imaging * Possible Neurological Surveillance * Patient in limitation of active therapeutics or with high probability of soon limitation of active therapeutics * Intra-parenchymal frontal haematoma limiting the quality of measurement, diagnosed on imaging (Less than 25mm deep from the skin) * Patient in limitation of active therapeutics or with high probability of soon limitation of active therapeutics * Adhesive allergy to measuring patches * Patient under guardianship or safeguard of justice * Refusal of legal representative

Design outcomes

Primary

MeasureTime frameDescription
Permanent measurement of cerabral oxymetry (rSO2) by NIRS systemFrom day 4 to day 12 post aneurysmal subarachnoid hemorrhageDifference between NIRS basal measurement entre la mesure basale du NIRS (NIRS average on the first hour of recording respectively on the left and right) and the NIRS measurement during the follow-up (lowest mean NIRS observed over one hour in patients without vasospasm diagnosed by the reference test or mean NIRS observed over the hour.

Secondary

MeasureTime frameDescription
Severity of angiographic spasmDay 8 post aneurysmal subarachnoid hemorrhageNot significant (\<50%) Significant (\>50%) Severe.
Pti02 valueDay 4 post aneurysmal subarachnoid hemorrhagePti02 value (mm Hg)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 3, 2026